⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients. Preclinical data robustly support its specific binding, favorable pharmacokinetics, and excellent safety profile, warranting its advancement into clinical studies.
**Inclusion Criteria**
Subjects must voluntarily sign the informed consent form and be able to complete the trial per the protocol requirements.
Age 18 years or older, regardless of gender.
Diagnosed with multiple myeloma and scheduled to receive anti-BCMA CAR-T cell therapy.
**Exclusion Criteria**
Participation in another interventional clinical trial, concurrently or within 28 days prior to the first dose in this study. Participation in non-interventional trials is permitted.
History of hypersensitivity to any component of the imaging agent or antibodies, or a known allergic predisposition.
Inability to undergo PET/CT imaging, such as due to claustrophobia or emotional instability.